SGEN:

*Data is delayed | MXN
after hours iconAfter Hours: Last |
quote price arrow down ()
Close
quote price arrow down ()
52 week range
-
Loading...
  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High-
  • 52 Week High Date-
  • 52 Week Low-
  • 52 Week Low Date-

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High-
  • 52 Week High Date-
  • 52 Week Low-
  • 52 Week Low Date-
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On undefined

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal...
Address
21717 30th Drive S.E., Building 3
Bothell, WA
98021
United States